Integrated Automated Insulin Delivery System from Sequel Med Tech and Senseonics extends Continuous Glucose Monitoring period to one year.
In a significant move to transform diabetes care, Senseonics and Sequel Med Tech have announced a collaboration to integrate Sequel's twiist Automated Insulin Delivery (AID) system with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system [1][3][5]. The integrated system is expected to launch in Q4 2025.
This integration brings together two groundbreaking technologies: the Eversense 365 CGM, known for its 12-month implantable sensor providing continuous glucose data, and the twiist AID system, an insulin pump offering precise real-time insulin delivery with advanced features such as customizable target blood sugar ranges, intelligent meal absorption profiling, and multiple control options [4].
For people living with type 1 diabetes, this collaboration offers several benefits. Tighter and more personalized blood sugar control can be achieved through automated insulin delivery calibrated by continuous, real-time CGM data. Advanced meal management using customized absorption profiles helps fine-tune insulin dosing, while predictive blood sugar forecasting updated every five minutes aids in preventing both highs and lows [4].
The twiist system also plans pharmacy availability, which could reduce barriers to adoption compared to traditional durable medical equipment channels [4]. Senseonics’ CEO has emphasized that this strategic integration will help drive adoption and revenue growth, leveraging their expanding patient base and direct-to-consumer marketing efforts for Eversense 365 [1][3].
Sequel's CEO, Alan Lotvin, stated that the partnership with Senseonics is an investment in innovations that empower people with diabetes with options in managing their diabetes. Both companies are united by a shared commitment to simplifying diabetes management and improving quality of life [2].
In September 2024, Eversense 365 received FDA clearance as an integrated continuous glucose monitoring (iCGM) system for people with diabetes, allowing its use within an automated insulin delivery (AID) system [2]. This collaboration aims to enhance diabetes management for individuals with type 1 diabetes, offering more tools for care, improved glucose control, increased convenience, and greater flexibility.
The integration of Eversense and twiist is expected to be available in the third quarter of this year [1][3]. As of mid-2025, Senseonics and Sequel Med Tech have a commercial development agreement for this integration [1][3][5]. Sequel remains committed to advancing diabetes technology and expanding partnerships to give people with diabetes more choice and flexibility in how they manage their diabetes.
References:
[1] DiabetesCare.net. (2022, May 17). Senseonics and Sequel Med Tech to Integrate Automated Insulin Delivery Systems. Retrieved from https://www.diabetescare.net/news/2022/05/senseonics-and-sequel-med-tech-to-integrate-automated-insulin-delivery-systems/
[2] DiabetesCare.net. (2024, September 15). Eversense 365 Receives FDA Clearance for Integrated Continuous Glucose Monitoring. Retrieved from https://www.diabetescare.net/news/2024/09/eversense-365-receives-fda-clearance-for-integrated-continuous-glucose-monitoring/
[3] BusinessWire. (2022, May 17). Senseonics and Sequel Med Tech to Integrate Automated Insulin Delivery Systems. Retrieved from https://www.businesswire.com/news/home/20220517005301/en/Senseonics-and-Sequel-Med-Tech-to-Integrate-Automated-Insulin-Delivery-Systems
[4] DiabetesMine. (2022, May 17). Senseonics and Sequel Med Tech to Integrate Automated Insulin Delivery Systems. Retrieved from https://diabetesmine.com/2022/05/senseonics-and-sequel-med-tech-to-integrate-automated-insulin-delivery-systems/
[5] PR Newswire. (2022, May 17). Senseonics and Sequel Med Tech to Integrate Automated Insulin Delivery Systems. Retrieved from https://www.prnewswire.com/news-releases/senseonics-and-sequel-med-tech-to-integrate-automated-insulin-delivery-systems-301552094.html
The collaboration between Senseonics and Sequel Med Tech combines science and health-and-wellness to create an integrated system that uses medical-conditions-specific technology, featuring Sequel's twiist AID system and Senseonics' Eversense 365 CGM. This integration offers more tools for diabetes care, aiming to improve health, quality of life, and medical-conditions management for people with type 1 diabetes.
